<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To analyse the outcome of allogeneic peripheral blood stem cell transplantation (allo-PBSCT) for <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Twenty-three patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> received G-CSF mobilized HLA-identical sibling allo-PBSCT </plain></SENT>
<SENT sid="2" pm="."><plain>The numbers of mononuclear cells (MNC) and CD34+ cells were 8 </plain></SENT>
<SENT sid="3" pm="."><plain>25 (4.50 -22.36) x 10(8)/kg and 5.59 (1.57 - 12.22) x 10(6)/kg respectively </plain></SENT>
<SENT sid="4" pm="."><plain>CsA and shorten course MTX were used for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) prophylaxis and MMF was given on + 1 d - +28 d posttransplantation </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Among 23 patients, 22 achieved hematopoietic recovery </plain></SENT>
<SENT sid="6" pm="."><plain>The median time of ANC &gt; 1.0 x 10(9)/L and BPC &gt; 50 x 10(9)/L were + 13 (+ 11 - +17) days and + 30 (+13 + 102) days respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Two patients died of transplant related complications and three died of disease relapse, while 18 patients survived </plain></SENT>
<SENT sid="8" pm="."><plain>Kaplan-Meier analysis showed disease free survival and relapse rate were (77.8 +/- 8.7)% and (14.4 +/- 7.5)% respectively </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Allo-PBSCT is an effective treatment for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
</text></document>